Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.

Abstract

Authors

• Rana R Mckay
  University of California San Diego, San Diego, CA, USA.
• Bruce Montgomery
  Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA.
• Wanling Xie
  Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
• Zhenwei Zhang
  Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
• Glenn J Bubley
  Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
• David W Lin
  Department of Urology, University of Washington, Seattle, WA, USA.
• Mark A Preston
  Department of Surgery, Division of Urology, Dana Farber/Brigham and Women's Cancer Center, Boston, MA, USA.
• Quoc-Dien Trinh
  Department of Surgery, Division of Urology, Dana Farber/Brigham and Women's Cancer Center, Boston, MA, USA.
• Peter Chang
  Department of Urology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
• Andrew A Wagner
  Department of Urology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
• Elahe A Mostaghel
  Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA.
• Philip W Kantoff
  Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• Peter S Nelson
  Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA.
• Adam S Kibel
  Department of Surgery, Division of Urology, Dana Farber/Brigham and Women's Cancer Center, Boston, MA, USA.
• Mary-Ellen Taplin
  Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Mary_Taplin@DFCI.harvard.edu.

Keywords

External Resources